Neurochemical impact of the 5-HT 2C receptor agonist WAY-163909 on monoamine tissue content in the rat brain

Abdeslam Chagraoui, Sara Whitestone, Lynn Baassiri, Julien Manem, Giuseppe Di Giovanni, Philippe De Deurwaerdère
Neurochemistry International. 2019-03-01; 124: 245-255
DOI: 10.1016/j.neuint.2019.01.019

Lire sur PubMed

Chagraoui A(1), Whitestone S(2), Baassiri L(2), Manem J(2), Di Giovanni G(3), De Deurwaerdère P(4).

Author information:
(1)Normandie Univ, UNIROUEN, INSERM, U1239, CHU Rouen, Neuronal and Neuroendocrine Differentiation and Communication Laboratory, Institute for Research and Innovation in Biomedicine of Normandy (IRIB), Rouen, France; Department of Medical Biochemistry, Rouen University Hospital, Rouen, France.
(2)Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5287, 33076, Bordeaux Cedex, France.
(3)Department of Physiology & Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida, Malta; Neuroscience Division, School of Biosciences, Cardiff University, Cardiff, UK.
(4)Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5287, 33076, Bordeaux Cedex, France. Electronic address: .

Serotonin2C receptor (5-HT2C) agonists are promising drugs for the treatment of neuropsychiatric diseases. However, their effect is not completely understood in part because they possibly affect several neurobiological networks simultaneously. We studied the effect of the 5-HT2C receptor agonist WAY-163909 (0.3 and 3 mg/kg; i.p.) on the tissue concentration of dopamine (DA), 5-HT and noradrenaline (NA) in 29 rat brain regions related to motor, cognitive, mood and vegetative networks. We found that WAY-163909, without altering the tissue  concentration of NA, increased 5-HT concentrations in the medial orbitofrontal cortex and the motor cortex M2 at 3 mg/kg and decreased it in the dorsolateral orbitofrontal cortex at 0.3 mg/kg. WAY-163909 enhanced DA concentrations in the central nucleus of the amygdala at 0.3 mg/kg and reduced it in the dorsal hypothalamus at 3 mg/kg. Using correlative analysis of the tissue content of monoamines, WAY-163909 dramatically changed the profile and the pattern of the correlations within and between monoaminergic systems without drastically changing the total number of these correlations. The profile of these changes in correlations was dose-dependent as it was very different between the two doses within and among monoaminergic systems. In conclusion, the data indicated that the 5-HT2C receptor agonist WAY-163909 quantitatively alters monoamine content in very few regions but promotes multiple changes of monoaminergic connectivity in the brain.


Auteurs Bordeaux Neurocampus